



Fera Pharmaceuticals is pleased to announce that it has completed an agreement with Pfizer to acquire Phospholine Iodide®

To address long-term supply, Fera and Pfizer have completed an agreement to immediately transfer Phospholine Iodide to Fera. Fera has the capabilities, experience, and motivation to bring Phospholine Iodide to patients on a sustainable and expedited basis. Led by a seasoned executive team including Frank DellaFera, former CEO of Sandoz US, Fera was selected based on multiple factors, including expertise and focus in ophthalmic medicines, experience in bringing complex medicines to patients, and their understanding of the regulatory process for ophthalmic medicines.

As part of the agreement, Pfizer will transfer the New Drug Application for Phospholine Iodide, the trademark, and existing inventory to Fera Pharmaceuticals. Additionally, Pfizer will provide technical consultation services to Fera to help progress the development and manufacturing of the product in an expedited manner. Fera is prepared to complete the transition as soon as possible and has experience working with the FDA to expedite product approval and subsequent return to market for products that are complex to manufacture.

Fera is optimistic that we will progress the development and manufacturing of Phospholine Iodide in an expedited manner with a reliable and compliant manufacturing supply chain.